Cargando…

Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature

INTRODUCTION: The aim of this study is to rigorously review the efficacy and safety of olanzapine in defined hematology oncology settings including (1) the setting of highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) settings (2) at 5 mg and 10 mg doses, and (3) for r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chow, Ronald, Herrstedt, Jørn, Aapro, Matti, Chiu, Leonard, Lam, Henry, Prsic, Elizabeth, Lock, Michael, DeAngelis, Carlo, Navari, Rudolph M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805431/ https://www.ncbi.nlm.nih.gov/pubmed/33442782 http://dx.doi.org/10.1007/s00520-020-05935-7

Ejemplares similares

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis
por: Chelkeba, Legese, et al.
Publicado: (2017)

A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting
por: Wang, Xiao-fei, et al.
Publicado: (2014)

Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
por: Navari, Rudolph M.
Publicado: (2015)

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy
por: Navari, Rudolph M
Publicado: (2009)

Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes
por: Herrstedt, Jørn, et al.
Publicado: (2021)

Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting
por: Ruhlmann, Christina, et al.
Publicado: (2009)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction
por: Aapro, Matti
Publicado: (2018)

Olanzapine: An Antiemetic Option for Chemotherapy-Induced Nausea and Vomiting
por: Brafford, Megan V., et al.
Publicado: (2014)

Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles
por: Navari, Rudolph, et al.
Publicado: (2022)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts
por: Aapro, Matti
Publicado: (2018)

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
por: Tan, Lijun, et al.
Publicado: (2009)

Olanzapine in the Treatment of Refractory Nausea and Vomiting in Palliative Care Settings
por: Gupta, Nishkarsh, et al.
Publicado: (2018)

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014)

The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
por: Eghbali, Aziz, et al.
Publicado: (2023)

Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron
por: Zhou, Michelle, et al.
Publicado: (2015)

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan
por: Osman, Alaa A.M., et al.
Publicado: (2018)

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Olanzapine and Betamethasone Are Effective for the Treatment of Nausea and Vomiting due to Metastatic Brain Tumors of Rectal Cancer
por: Suzuki, M., et al.
Publicado: (2014)

Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer
por: Wang, Wenxian, et al.
Publicado: (2018)

The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron.
por: Aapro, M. S., et al.
Publicado: (1994)

Oncologist perspectives on chemotherapy‐induced nausea and vomiting (CINV) management and outcomes: A quantitative market research‐based survey
por: Aapro, Matti, et al.
Publicado: (2018)

Comparison of Mirtazapine and Olanzapine on Nausea and Vomiting following Anthracycline-cyclophosphamide Chemotherapy Regimen in Patients with Breast Cancer
por: Maleki, Alimohammad, et al.
Publicado: (2020)

Olanzapine 5 mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy
por: Wang, Jun, et al.
Publicado: (2022)

Olanzapine enhances the effect of conventional drugs in chemotherapy inducing nausea and vomiting: A randomized clinical trial
por: Khani, Atefe, et al.
Publicado: (2022)

Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience
por: Uchiike, Akihiro, et al.
Publicado: (2023)

Dextrose for post-operative nausea and vomiting prophylaxis
por: Castro-Alves, Lucas J, et al.
Publicado: (2018)

Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis
por: Schwartzberg, Lee, et al.
Publicado: (2023)

One‐Day Versus Three‐Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy‐Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data‐Based Meta‐Analysis
por: Okada, Yuki, et al.
Publicado: (2019)

Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal
por: Dulal, Soniya, et al.
Publicado: (2019)

Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug
por: Zhang, Xiao-Ling, et al.
Publicado: (2022)

Palonosetron as an anti-emetic and anti-nausea agent in oncology
por: Aapro, Matti S
Publicado: (2007)

Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials
por: Celio, Luigi, et al.
Publicado: (2012)

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)
por: Navari, Rudolph M, et al.
Publicado: (2023)

Postoperative nausea and vomiting
por: Moon, Young Eun
Publicado: (2014)

The big “little problem” with postoperative nausea and vomiting prophylaxis
por: Chilkoti, G, et al.
Publicado: (2015)

Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis
por: Kim, Won Oak, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_t3b365e53jh8s1lphiee35ck0u